Company news
Psyence Biomedical Ltd. (NASDAQ:PBM) news
Psyence Biomedical Ltd. news releases on 6ix. Latest, Dec 6, 2024: Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical…
Press releases — page 2
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
December 5, 2024
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
December 2, 2024
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
November 19, 2024
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
November 18, 2024
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
November 11, 2024
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
October 30, 2024
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
October 30, 2024
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
October 23, 2024
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
October 16, 2024
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
October 13, 2024
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
October 3, 2024
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
September 19, 2024
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
September 18, 2024
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
September 15, 2024
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
September 15, 2024
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
September 12, 2024
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
September 8, 2024
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
September 5, 2024
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
September 3, 2024
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
August 29, 2024
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
July 30, 2024
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
July 25, 2024
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
July 23, 2024